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Abstract
Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding syndrome affecting the
megakaryocyte lineage and characterized by lack of platelet aggregation. The molecular basis is
linked to quantitative and/or qualitative abnormalities of αIIbβ3 integrin. This receptor mediates
the binding of adhesive proteins that attach aggregating platelets and ensure thrombus formation
at sites of injury in blood vessels. GT is associated with clinical variability: some patients have only
minimal bruising while others have frequent, severe and potentially fatal hemorrhages. The site of
bleeding in GT is clearly defined: purpura, epistaxis, gingival hemorrhage, and menorrhagia are
nearly constant features; gastrointestinal bleeding and hematuria are less common. In most cases,
bleeding symptoms manifest rapidly after birth, even if GT is occasionally only diagnosed in later
life. Diagnosis should be suspected in patients with mucocutaneous bleeding with absent platelet
aggregation in response to all physiologic stimuli, and a normal platelet count and morphology.
Platelet  αIIbβ3 deficiency or nonfunction should always be confirmed, for example by flow
cytometry. In order to avoid platelet alloimmunisation, therapeutic management must include, if
possible, local hemostatic procedures and/or desmopressin (DDAVP) administration. Transfusion
of HLA-compatible platelet concentrates may be necessary if these measures are ineffective, or to
prevent bleeding during surgery. Administration of recombinant factor VIIa is an increasingly used
therapeutic alternative. GT can be a severe hemorrhagic disease, however the prognosis is
excellent with careful supportive care.
Disease name
Glanzmann thrombasthenia (GT)
Definition/diagnostic criteria
GT is an autosomal recessive bleeding syndrome affecting
the megakaryocyte lineage and characterized by a lack of
platelet aggregation. It is a moderate to severe hemor-
rhagic disorder with mainly mucocutaneous bleeding.
The molecular basis is linked to quantitative and/or qual-
itative abnormalities of αIIbβ3 integrin, the receptor that
mediates the incorporation of platelets into an aggregate
or thrombus at sites of vessel injury.
Glanzmann first described this disease in 1918 as "hered-
itary hemorrhagic thrombasthenia" [1]. A prolonged
bleeding time and an isolated, rather than clumped,
appearance of platelets on a peripheral blood smear were
early diagnostic criteria. In 1956, Braunsteiner and Pake-
sch reviewed disorders of platelet function and described
thrombasthenia as an inherited disease characterized by
platelets of normal size that failed to spread onto a surface
and did not support clot retraction [2]. The diagnostic fea-
tures of GT including the absence of platelet aggregation
as the primary feature were clearly established in 1964 by
the classic report on 15 French patients by Caen et al. [3].
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Those patients with absent platelet aggregation and
absent clot retraction were subsequently termed as having
type I disease; those with absent aggregation but residual
clot retraction, type II disease; while variant disease was
first established in 1987 (reviewed in ref [4]).
Differential diagnosis
Platelet aggregation defects specific to adenosine diphos-
phate (ADP) or collagen, imply abnormalities of their pri-
mary receptors or of signaling pathways. Defects in the
second wave of aggregation to ADP or in the response to
collagen can imply storage pool disease and an absence of
the secretory stores of ADP in dense granules. Deficiencies
in the platelet response to arachidonic acid can point
either to an inherited abnormality in thromboxane A2
formation or a platelet function defect temporarily
acquired through aspirin ingestion. GT is the only disease
in which platelet aggregation is defective to all agonists,
while absent clot retraction is another frequent character-
istic.
Normal ristocetin-induced platelet agglutination and nor-
mal platelet size clearly rule out the Bernard-Soulier syn-
drome, a disorder of platelet adhesion. Inherited
thrombocytopenias are eliminated by a normal platelet
count. Normal coagulation parameters rule out clotting
disorders that can also affect platelet function such as con-
genital afibrinogenemia and von Willebrand disease.
Acquired thrombasthenia must be eliminated in the
absence of a family history of the disease. Platelet αIIbβ3
deficiency and abnormal platelet aggregation have been
reported in patients with acute promyelocytic leukemia
[5]; the etiology of this acquired disorder is probably a
chromosome 15–17 translocation. Although the break-
point region on chromosome 17 is heterogeneous in
acute promyelocytic leukemia, in some patients it occurs
at 17q21, and this is the location of the genes for αIIb and
β3 [6]. Another problem in diagnosing GT is to eliminate
patients with acquired autoantibodies that block aggrega-
tion, although these patients would often be thrombocy-
topenic [7]. These antibodies can be detected
immunologically by their binding to αIIbβ3 of control
platelets during incubation with the patient's serum [8].
Etiology
Cell biology
Megakaryocytes are found in the bone marrow and when
mature, liberate large numbers of platelets into the blood
circulation. In GT, platelets fail to aggregate in response to
all natural agonists, including ADP, thrombin and colla-
gen, despite their undergoing a normal shape change.
Thrombasthenic platelets can also adhere to exposed sub-
endothelial tissue and secretion from storage granules is
initiated. However, the subsequent reactions of platelet
spreading on the exposed surface and thrombus build-up
are defective [9]. In the 1970s, Nurden and Caen demon-
strated that platelets from patients with GT had selective
abnormalities in their membrane glycoprotein (GP) com-
position [10]. This led to the recognition that the disease
was provoked by specific deficiencies of GPIIb and GPIIIa.
It was later established that (i) GPIIb and GPIIIa were
present in the platelet membrane as a heterodimeric mol-
ecule and (ii) like αIIbβ3, the complex was a member of
the ubiquitous integrin family of cell surface receptors
[11,12]. Significantly, GT is now generally recognized as
the most frequent inherited integrin disorder.
In man, expression of the αIIb gene (ITGA2B) (and there-
fore of αIIbβ3 integrin) is restricted to cells of the meg-
akaryocytic cell lineage. Expression of the β3  gene
(ITGB3) is more widespread, with the vitronectin receptor
(αvβ3) being expressed in many cell types, including
endothelial cells, osteoblasts, smooth muscle cells, and
leukocytes [12]. Despite this, patients with β3 gene defects
appear not to have a more severe form of the disease (dis-
cussed below). In the platelet, αvβ3 is a rare component,
approximately 50 copies being found at the surface, com-
pared to over 50,000 copies of αIIbβ3 [13]. In the seconds
following binding of stimuli to platelets, αIIbβ3 straight-
ens from a bent conformation and demonstrates receptor
activity for fibrinogen [14]. Although fibrinogen is the
predominant ligand in plasma, the role of von Willebrand
factor (VWF) in conditions of high shear should be
emphasized, while fibronectin, vitronectin and CD40L
may also participate [15-17]. The inability to bind adhe-
sive proteins when stimulated explains the platelet phe-
notype in GT. Fibrin binding to αIIbβ3 allows some
hemostatic function when residual integrin is present
[18]. Furthermore, GT platelets appear able to attach to
fibrin (independently of activated αIIbβ3) under flow,
suggesting the presence of an alternative platelet receptor
for fibrin [19].
Genetic basis
A continually updated database is available on the Inter-
net http://sinaicentral.mssm.edu/intranet/research/glanz
mann: it currently contains a list of about 100 mutations
giving rise to GT. The αIIb and β3 genes are both affected
and while posttranslational defects predominate, mRNA
stability can also be reduced. In brief, integrin synthesis
occurs in the megakaryocytes with αIIbβ3 complex forma-
tion in the endoplasmic reticulum (ER). Noncomplexed
or incorrectly folded gene products fail to undergo
processing in the Golgi apparatus and are rapidly
degraded intracellularly [20,21]. One exception is the
ability of normally synthesized β3 to complex with αv and
form αvβ3 (see above). Figures 1 and 2 show those muta-
tions where supplementary information (family studies,
site-directed mutagenesis) links them to the GT pheno-
type. Deletions and insertions, nonsense and missenseOrphanet Journal of Rare Diseases 2006, 1:10 http://www.OJRD.com/content/1/1/10
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mutations are common causes of GT. Splice site defects
and frameshifts are also widespread. Large deletions are
rare.
As shown in Figure 1, the αIIb gene is composed of 30
exons. In an early and classic study, three Israeli-Arab kin-
dreds were shown to possess a 13-bp deletion leading to a
six-amino acid deletion in the αIIb protein [22]. The
affected region, including Cys107, was postulated to be
critical for posttranslational processing of αIIb. Missense
mutations in exons encoding the extracellular β– propel-
ler region of αIIb [23] have shown how the extracellular
calcium-binding domains of αIIb are essential for αIIbβ3
biogenesis [24-26]. Site-directed mutagenesis involving
various amino acid substitutions at position 324 of αIIb,
illustrated to what extent the GT phenotype depended on
both the nature of the substituted amino acid and its
replacement [26]. Mutations affecting the membrane-
proximal calf-2 domain showed that while this region was
not essential for complex formation in the ER, it was nec-
essary for transport into and/or through the Golgi appara-
tus [21,27]. These are but a few selected examples of αIIb
defects.
The organization of the β3 gene is shown in Figure 2. It is
composed of 15 exons and mutations are again widely
distributed within the gene. An 11 bp deletion leading to
protein termination shortly before the transmembrane
domain of β3 was first described in six Iraqi Jews with type
I disease [22]. This defect prevented normal membrane
Schematic representation of the structure of the GPIIb (aIIb) gene (ITGA2B) together with a representative spectrum of the  types of genetic abnormalities that give rise to Glanzmann thrombasthenia (GT) Figure 1
Schematic representation of the structure of the GPIIb (αIIb) gene (ITGA2B) together with a representative spectrum of the 
types of genetic abnormalities that give rise to Glanzmann thrombasthenia (GT). The defects responsible for variant forms of 
the disease are in blue type, those which are prevalent in ethnic groups are in green. Asterisks indicate the number of times 
that the same genetic defect has been described in apparently unrelated families. For a continually updated list of defects please 
consult the ISTH database http://sinaicentral.mssm.edu/intranet/research/glanzmann. UTR: untranslated region, del = deletion, 
ins = insertion, inv = inversion, term = premature termination, stop = stop codon. For simplicity, the initial genetic defect is 
highlighted. Frameshifts and aberrant splicing are not always noted.Orphanet Journal of Rare Diseases 2006, 1:10 http://www.OJRD.com/content/1/1/10
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insertion of the integrin and also αvβ3 expression, both in
platelets and other cells. Although most β3  mutations
affect αIIbβ3 and αvβ3 expression, rare mutations allow
αvβ3 expression while preventing αIIbβ3 processing [28].
Patients with mutations allowing αIIbβ3 to be processed,
but in whom integrin function is abolished, are of partic-
ular interest. In most of these patients, it is the β3 gene
that is affected. In brief, many of the variants have plate-
lets with sufficient αIIbβ3 to normally allow aggregation,
but the activation-dependent expression of adhesive pro-
tein binding sites on the integrin does not occur [29,30].
As well as providing information on the ligand-binding
pocket on the extracellular domains, variant molecules
have highlighted the role of the αIIb and β3 intracellular
tails in integrin signaling and even for integrin trafficking
[31-33]. For some variants, clot retraction can occur even
if aggregation is prevented [34]. Finally, recent studies on
two patients have revealed that disruption of disulfide
bridges in the β3 Epidermal Growth Factor (EGF) extracel-
lular domains gives rise to a constitutively active integrin,
able to spontaneously bind fibrinogen [35,36]. Here,
aggregation fails to occur because of the absence of free
counter receptors allowing platelet to platelet bridging.
The recent application of mutation screening on a
national basis, first in Italy and then in India, has re-
emphasized how a wide array of mutations can be found
in GT patients within a single country. Interestingly, while
17 out of 21 candidate mutations were in the αIIb gene of
the Italian patients, β3 mutations with emphasis on exon
4 appear to characterize the Indian patients [37,38].
Clinical description
Early reports emphasized the clinical variability of this
bleeding syndrome: some patients had only minimal
bruising, while others had frequent, severe and potentially
fatal hemorrhages. Hemorrhagic symptoms occur only in
Sematic representation of the structure of the GPIIIa (β3) gene (ITGB3) together with a representative spectrum of the types  of genetic abnormalities that give rise to Glanzmann thrombasthenia (GT) Figure 2
Schematic representation of the structure of the GPIIIa (β3) gene (ITGB3) together with a representative spectrum of the 
types of genetic abnormalities that give rise to Glanzmann thrombasthenia (GT). Note that abnormalities are abundant in both 
αIIb and β3 genes and that no parts of either gene appear to be exempt. For further information see the legend to Figure 1.Orphanet Journal of Rare Diseases 2006, 1:10 http://www.OJRD.com/content/1/1/10
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patients homozygous for mutations causing GT; the heter-
ozygous condition is mostly asymptomatic, even though
these subjects have only a half-normal concentration of
platelet αIIbβ3 [4]. The sites of bleeding in GT are clearly
defined: purpura, epistaxis, gingival hemorrhage, and
menorrhagia are nearly constant features; gastrointestinal
bleeding and hematuria are less common but can cause
serious complications [39,40]. It is important to note that
deep visceral hematomas, a characteristic of coagulation
disorders such as hemophilia, are not usually seen. In
most cases, bleeding symptoms manifest rapidly after
birth, even if occasionally GT is only diagnosed later in
life. Epistaxis is a common cause of severe bleeding, and
is typically more severe in childhood. In general, the
bleeding tendency in GT decreases with age. The rare co-
existence of GT with other inherited diseases, such as mild
von Willebrand disease, may accentuate the clinical sever-
ity of bleeding [27,39].
Although GT can be a severe hemorrhagic disease, the
prognosis is excellent with careful supportive care. Most
adult patients are in good health and their disease has a
limited effect on their daily lives. Death from hemorrhage
in diagnosed patients is rare unless associated with
trauma or other disease (e.g. cancer). In contrast, families
often report deceased siblings on diagnosis of GT.
Correlation of clinical disease with the molecular platelet 
abnormality
Clinical observations suggest little or no correlation
between the amount of residual platelet αIIbβ3 and the
severity of hemorrhagic disease [4,39]. Among the
patients studied over many years in Paris [4], some with
negligible bleeding symptoms have virtually no detecta-
ble αIIbβ3, while others who have 10%–15% of the nor-
mal level of functional platelet αIIbβ3 have experienced
severe hemorrhage. It can be postulated that the absence
of αvβ3 function in vascular cells may contribute to the
hemorrhagic tendency. However, even among families in
whom β3 is undetectable, bleeding ranges from severe to
moderate and sporadic. Since therapeutic inhibition of
platelet αIIbβ3 function prevents arterial thrombosis [41],
patients are empirically protected from this disease. It has
been speculated that patients with GT may also be pro-
tected from atherosclerotic disease. However, studies
within ethnic groups in Israel have suggested that this is
not so [42]. Patients with GT also are not protected against
venous thrombosis, where plasma coagulation factors are
of primary importance [43].
Mice lacking β3 integrins develop thickened bones
because of dysfunctional osteoclasts [44]. However,
upregulation of α2β1 integrin compensates for lack of
αvβ3 in osteoclasts from Iraqi-Jewish patients and so this
feature may not translate to humans [45]. Other studies
with β3 knockout mice show increased expression of Flk-
1 on β3-null endothelial cells with increased vascular EGF
(VEGF) signaling and enhanced angiogenesis and tumor
growth [46]. How this or an observed decreased fertility
translate to GT patients with β3 gene defects are topics for
urgent study.
Epidemiology
A review of 177 patients with GT (of which 113 were liter-
ature reports and 64 were seen at the Hôpital Lariboisière,
Paris) showed that 102 (58%) of the patients were female
[4]. This finding may reflect the added problem of menor-
rhagia. The average age of the 113 patients for whom age
was given was only 20. This may reflect improvements in
diagnostic procedures. The frequency of consanguinity in
affected families is noticeable, and GT has an increased
incidence in populations in whom marriage among close
relatives is an accepted custom. For example, in the review
of 177 patients [4], only 12 were from the United States.
In contrast, 55 patients were from Israel and Jordan, and
42 were from South India. In certain ethnic groups, such
as South Indian Hindus, Iraqi Jews, French gypsies and
Jordanian nomadic tribes, thrombasthenia may actually
be a common hereditary hemorrhagic disorder. This has
recently been borne out by a report of 382 patients in Iran
[47]. For these reasons, it would be imprudent to give an
estimation of worldwide prevalence.
Diagnostic methods
Mucocutaneous bleeding with absent platelet aggregation
in response to all physiologic stimuli is pathognomonic
for GT, and abnormal clot retraction is rarely observed in
other disorders [39]. When these two signs are associated
with a normal platelet count and morphology, the diag-
nosis of GT is clear-cut. Use of the PFA-100 system (Dade-
Behring, Miami, USA) can replace bleeding time tests for
GT [48]. The PFA-100 measures the closure time when
blood is passed through collagen-based filters under flow;
blood from GT patients fails to plug the filter. Platelet
αIIbβ3 deficiency should always be confirmed in new
patients, and this can be done with monoclonal antibod-
ies and flow cytometry [24,35]. The detection of trace
amounts of intracellular αIIb or β3 in a patient's platelets
by western blotting [27,28], can give clues to the identity
of the affected gene, while the presence of nonprocessed
precursor pro-αIIb will suggest a block in integrin biosyn-
thesis [25,26].
In the detailed analysis of experience gained at Hôpital Lar-
iboisière in Paris, 50 out of 64 patients (78%) had type I
disease, nine patients (14%) had type II disease with
residual αIIbβ3, and five patients (8%) were classified as
variant GT [4], a subgroup diagnosed by the inability of
αIIbβ3 to express activation-dependent epitopes (recog-
nized by the absence of binding of monoclonal antibod-Orphanet Journal of Rare Diseases 2006, 1:10 http://www.OJRD.com/content/1/1/10
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ies, such as PAC-1 or FITC-fibrinogen, in flow cytometry)
[29-34].
Procedures permitting the rapid screening of given muta-
tions can only be used in ethnic groups with high consan-
guinity. This is the case for the Iraqi-Jewish and Arab
groups in Israel and for a Manouche gypsy population in
France [49-51]. Here, rapid screening procedures include
allele-specific restriction enzyme analysis (ASRA) [51].
Otherwise, the patient needs to be referred to a specialist
laboratory, for direct sequencing of the relevant genes.
Carrier analysis, prenatal diagnosis and genetic 
counseling
Initial studies attempted to diagnose carriers of GT by
measuring the number of αIIbβ3 receptors on platelets.
However, an occasional overlap between obligate hetero-
zygotes and ostensibly normal donors, whose platelets
had a low αIIbβ3 expression, made interpretation of the
results difficult. Prenatal diagnosis performed by measur-
ing αIIbβ3 on platelets isolated from cord blood has been
attempted, but is accompanied by a high risk of bleeding
and of spontaneous abortion [52]. It is therefore best to
first identify the genetic lesion within the family in ques-
tion. Carrier diagnosis can then be determined with rela-
tive ease particularly if sites are created (or lost) for
restriction enzymes. Restriction digest analysis of
polymerase chain reaction (PCR)-amplified fragments
from DNA isolated from blood or urine was first used to
screen subjects for the Iraqi-Jewish and Arab mutations
[49]. The presence of these mutations could also be con-
firmed in prenatal diagnosis using DNA extracted from
chorionic villi (discussed by French [20]). Carriers have
also been detected within the French gypsy populations
using ASRA methodology [51]. Finally, prenatal diagnosis
in GT has been achieved using the polymorphic markers
BRCA1 and THRA1 on chromosome 17 [53].
Genetic counseling can be given with the following reser-
vations: (i) when screening is followed for a single muta-
tion within an ethnic population, the presence of a second
Glanzmann's defect may go undetected and (ii) that indi-
viduals with the same mutation may differ widely in the
frequency and severity of bleeding.
Management including treatment
Despite variations in the severity and frequency of bleed-
ing episodes, most GT patients receive blood transfusions
[39,40]. Local bleeding can be treated by local measures,
such as fibrin sealants. Epistaxis and gingival bleeding are
successfully controlled in most patients by nasal packing
or the application of gel foam soaked in topical thrombin.
Regular dental care is essential to prevent gingival bleed-
ing. For teeth extractions, or for hemorrhage accompany-
ing the loss of deciduous teeth, hemostasis can be
significantly improved by the application of individually
prepared plastic splints that provide physical support for
hemostasis.
Severe menorrhagia is a frequent clinical problem and is
usually associated with an excessively proliferative
endometrium caused by estrogen dominance. It can be
effectively treated with high doses of progesterone. Main-
tenance treatment with birth control pills should follow.
Severe gastrointestinal bleeding is a problem in isolated
cases. Iron deficiency anemia, which can develop insidi-
ously with gingival oozing or minor menorrhagia, is a fre-
quent problem.
Bleeding following trauma or surgical procedures can be
severe and transfusions are often given by precaution or
should be available on standby. Pregnancy and in partic-
ular, delivery, represent a particularly severe hemorrhagic
risk. Platelet transfusions are required not only prior to
delivery, but sometimes should be continued for at least a
week [39]. Successful delivery by Cesarean section, with
platelet transfusions, has been reported. Note that if plate-
let transfusions are required, the most HLA-compatible
platelet concentrates must be chosen in order to avoid
platelet anti-HLA alloimmunization.
The fact that most patients receive red cell and/or platelet
transfusions on more than one occasion, makes the pro-
duction of isoantibodies reactive with αIIbβ3 likely
[4,39]. Such antibodies are antigen-driven and are pro-
duced against different epitopes on the integrin [54]. They
may block platelet aggregation, and lead to the rapid
removal of transfused platelets by immune mechanisms.
Whether a particular category of patient is more likely to
form isoantibodies is as yet unknown. When present at
high titer, the antibodies cause patients to become refrac-
tory to further transfusions. Antibodies have been success-
fully removed prior to surgery by immunoadsorption on
Protein A Sepharose, although this is a complex procedure
whose use is restricted to specialized centers [55].
Recently, recombinant factor VIIa (NovoSeven®; Novo
Nordisk A/S, Malov, Denmark) has been successfully used
in GT and represents an alternative approach for early ces-
sation of bleeding, especially for patients with antibodies
and/or a history of refractoriness to transfusion [56]. It is
often used in association with anti-fibrinolytic agents.
Thromboembolic events are a rare but potential hazard.
Recombinant factor VIIa appears to enhance deposition of
the  αIIbβ3-deficient platelets on the subendothelial
matrix through their interaction with fibrin formed as a
result of increased thrombin generation [19]. The stability
of the newly-formed clot is increased and its permeability
decreased [57]. Nevertheless, the efficacity of recom-
binant factor VIIa in children with GT has been ques-
tioned [58]. Rarely, in some patients, the condition hasOrphanet Journal of Rare Diseases 2006, 1:10 http://www.OJRD.com/content/1/1/10
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been thought to be sufficiently serious for allogeneic
bone-marrow transplantation to be performed [39,59]. In
the first report, donors were siblings and the transplanta-
tion was successful [59].
Unresolved questions
Awaiting discovery, perhaps, are abnormalities of the cyto-
plasmic proteins now thought to regulate the activation
state of αIIbβ3 for adhesive proteins [60]. The observation
that a series of platelet receptor gene haplotypes can mark-
edly affect bleeding severity and bleeding times in patients
with von Willebrand disease type I [61], points to the
bleeding tendency in congenital disorders being governed
by the score of an ensemble of risk factors. As well as gene
polymorphisms affecting platelet receptors, those influ-
encing coagulation factors and the functioning of vascular
cells may also be involved. The application of proteomic
and gene microarray technologies to platelet disorders
such as GT may help determine whether bleeding risk in
individual patients can be predicted. Although the work is
at an early stage, animal models of gene therapy show that
GT may be an appropriate disease for such an approach
and research is progressing in this direction [62].
Finally, as national and international networks are set up,
and sequencing centers become involved in genotyping,
especially among ethnic groups and third world countries,
healthcare of GT will improve on a worldwide basis.
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